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Inactivation of RB is one of the hallmarks of cancer, however gaps remain in our under-
standing of how RB-loss changes human cells. Here we show that pRB-depletion results in
cellular reprogramming, we quantitatively measured how RB-depletion altered the tran-
scriptional, proteomic and metabolic output of non-tumorigenic RPE1 human cells. These
profiles identified widespread changes in metabolic and cell stress response factors pre-
viously linked to E2F function. In addition, we find a number of additional pathways that are
sensitive to RB-depletion that are not E2F-regulated that may represent compensatory
mechanisms to support the growth of RB-depleted cells. To determine whether these
molecular changes are also present in RB1−/− tumors, we compared these results to Reti-
noblastoma and Small Cell Lung Cancer data, and identified widespread conservation of
alterations found in RPE1 cells. To define which of these changes contribute to the growth of
cells with de-regulated E2F activity, we assayed how inhibiting or depleting these proteins
affected the growth of RB1−/− cells and of Drosophila E2f1-RNAi models in vivo. From this
analysis, we identify key metabolic pathways that are essential for the growth of pRB-deleted
human cells.
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pRB, the protein product of the Retinoblastoma susceptibilitygene (RB1), and E2 promoter binding factor (E2F) haveimportant and well-described roles in cell cycle control.
pRB binds to the activator E2Fs (E2F1-3) and one inhibitory E2F,
E2F41, and in collaboration with other pRB-family members and
E2Fs orchestrates the tight transcriptional control of E2F target
genes2. Through this activity, pRB functions to obstruct the
expression of E2F target genes that control cell cycle
progression3,4, metabolism5, and mitochondrial function6. Inac-
tivation of this regulatory process is one of the hallmarks of
cancer cells. The various mechanisms that disrupt pRB activity in
tumor cells include the loss or silencing of Cyclin-Dependent
Kinase (CDK) inhibitors, CDKN2A-D (p15, p16, p18, and
p19)7,8, amplification or over-expression of CDK49, 610 or Cyclin
D1 (CCND1)11–14, direct mutation the RB1 gene15–17, or
expression of viral oncoproteins that target pRB18,19. Irrespective
of the mechanism of inactivation, pRB-loss deregulates E2F-
dependent transcription.
Despite clear evidence of widespread disruption of the pRB
pathway in human cancers, our understanding of the ways that
pRB inactivation changes the molecular properties of human cells
is limited. The pRB literature has been dominated by transcrip-
tion studies and these have focused primarily on the changes seen
at canonical E2F targets20 and at genes encoding known cell cycle
regulators. However, a number of recent publications have
expanded the biological functions and mechanisms of action of
pRB. In particular, these studies have identified novel roles for
pRB in mitochondria function21, new pRB-interacting partners22,
and examined the overall changes to the proteome that appear in
Rb1 mutant mouse tissues23. These proteome profiling experi-
ments revealed, unexpectedly, that a major impact of Rb1 ablation
on the proteome involves changes in the levels of mitochondrial
proteins23. However, the full extent of the proteomic changes
caused by RB1-deletion was masked by a high degree of sample-
to-sample variation between organisms, a weakness that is
inherent to the profiling of tissue samples that contain complex
mixtures of cell types.
To obtain a picture of how pRB-loss changes human cells, we
generated a detailed and quantitative map. For this, we measured
how pRB-depletion alter the transcriptome, proteome, and
metabolome of cultured diploid non-tumorigenic Retinal Pigment
Epithelial 1 (RPE1) cells. We then compared these changes to
molecular events in RB1−/− Retinoblastoma tumors and Small
Cell Lung Cancer (SCLC) to understand how alterations within
model pRB-depleted RPE1 cells compared to primary patient
samples. Many of the changes we identify are directly linked to
dysregulated E2F function; however, a number of pathways with
limited links to E2F were also found. These findings suggest that
pRB-depletion affects both direct and indirect mechanisms that
prime cells for neoplastic growth. To interrogate which of these
changes were essential for the growth of cells with de-regulated
E2F function, we used an established E2f1-RNAi model in
Drosophila24. This data identified a collection of pathways that are
altered in pRB-depleted cells and important for the cellular growth
of these cells and highlight the complex and integrated cellular
reprogramming caused by pRB-depletion in cells and organisms.
Results
pRB-deletion results in widespread cellular changes. To assess
the effects of pRB-depletion, we asked how the knockdown of pRB
alters the transcriptome, proteome, and metabolome of RPE1 cells.
RPE1 cells were chosen as they are TERT-immortalized (but not
transformed) human cells that contain wild type and active pRB
(Supplementary Fig. 1A) and p53. RPE1 cells have been used in
many previous studies of pRB function and are known to display
changes in transcription4,25, chromatin organization26,27, and cel-
lular metabolism5 in response to pRB loss. pINDUCER11 Dox-
ycycline (DOX) inducible short hairpins (shRNAs) were employed
to deplete pRB or a Firefly Luciferase (FF) control sequence28.
RPE1 cells were infected with the respective pINDUCER11 con-
structs and FACS sorted using GFP to establish pools of stable cells.
For these experiments, we used two previously published shRNAs
that target different regions of the RB1 mRNA, RB25 and RB2628,
and a negative control sequence targeting Firefly (FF) Luciferase
(LUC). To determine the effects of pRB-depletion on the tran-
scriptome, we first subtracted genes that showed changed levels in
control cells that express Firefly Luciferase (FF), upon DOX treat-
ment. We then determined the baseline (−DOX) transcriptome
from FF, RB25, and RB26 and found no statistically significant
difference. Next, we compared the levels of gene expression in pRB-
depleted cells with their non-Doxycycline counterparts. This
enabled the removal of mRNA changes caused by the addition of
DOX and/or the production of the FF shRNA (LUC), and to
identify changes common to both pRB-targeting shRNAs. To
deplete pRB or LUC, we treated the respective RPE1 lines with
DOX and tracked shRNA expression (RFP) and pRB via western
blot. From this analysis, we find very homogenous RFP levels in
DOX-treated cells, suggesting even shRNA production (Supple-
mentary Fig. 1B) and reduced pRB levels after 6 days of DOX
treatment (Fig. 1a, Supplementary Fig. 1C, D). Strong shRNA-
mediated depletion of pRB was found in DOX-treated cells, inde-
pendent of confluency (Supplementary Fig. 1E). Cells at 90% con-
fluency were selected for this analysis. We next checked the protein
levels of the pRB homologs, RB Transcriptional Corepressor Like 1
(RBL1) or 2 (RBL2) following DOX treatment. From this analysis,
we found RBL2 levels unchanged and increased levels of the E2F
target, RBL1 (Supplementary Fig. 1F). In agreement with previous
studies23, we do not find altered growth rates (Supplementary
Fig. 2A) or cell cycle progression of pRB-depleted cells (Supple-
mentary Fig. 2B–E). We then used these cells to profile both DOX-
treated and untreated cells to measure mRNA changes using RNA-
sequencing (RNA-seq), the proteome using Tandem Mass Tag
Mass Spectrometry (TMT-MS) and the metabolome with Liquid
chromatography–mass spectrometry (LCMS).
To determine the effects of pRB-depletion on the transcriptome,
we first subtracted genes that showed changed levels in FF cells
upon DOX treatment. We then determined the baseline (−DOX)
transcriptome from FF, RB25, and RB26 and found no statistically
significant difference. Next, we compared the levels of gene
expression in pRB-depleted cells with their non-Doxycycline
counterparts. This enabled the removal of mRNA changes caused
by the addition of DOX and/or the production of a non-specific
FF shRNA (LUC), and to identify changes common to both pRB-
targeting shRNAs. This analysis identified 990 genes that were
upregulated in pRB-depleted cells and 164 that were down-
regulated (Fig. 1b) (Significant genes are FDR p-value <0.05 with
log2 fold-change >1) (Supplementary Data 1). FDR-adjusted Gene
Ontology (GO) analysis identified gene groups that were most
sensitive to pRB-loss. In agreement with previous reports, the
expression of cell cycle factors and the transcription machinery
were significantly upregulated (6.3 × 10−24) upon pRB-depletion
(Fig. 1c). Changes were also evident in additional categories,
including membrane genes and cell migration (Fig. 1c). Many of
these genes are known to be E2F targets genes29 (Fig. 1d).
To quantify the effects of pRB-depletion on the proteome
of RPE1 cells, the same panel of cells was profiled using
multiplexed quantitative proteomics using tandem mass tag
(TMT) reagent technology and the SPS-MS3 method for
accurate quantification30–32. The levels of 6551 proteins were
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quantified in all samples. In accordance with our RNA-seq
approach, the protein levels in pRB DOX-treated cells were
compared to untreated and normalized against FF DOX+ vs.
DOX-. As illustrated in Fig. 1e, pRB-knockdown caused
widespread changes to the proteome (Supplementary Data 2).
FDR-adjusted GO analysis of the 527 proteins that were
significantly (p < 0.05) changed in pRB-depleted cells, identified
a subset of pathways that differed from the set highlighted by the
RNA analysis. Protein pathways upregulated in the pRB-
depleted cells include pentose biosynthesis, purine salvage,
glucose and methionine metabolism, and the interferon
response (Fig. 1f). Only two GO groups are presented in the
proteins downregulated after pRB-knockdown: organelle orga-
nization and organic metabolism (Fig. 1f).
Independent experimental testing of omics data. These profiles
highlight that pRB-depletion results in widespread cellular
changes. To independently evaluate these changes, we first tested
the levels of a subset of genes that show altered expression fol-
lowing pRB-depletion using RT-PCR. For this analysis, we
selected two upregulated, ARL14 and SERPINA9, and four
downregulated genes, RB1, IL18, TPI and PGK1, from our RNA-
seq data for independent testing. RT-PCR of these genes from
control and pRB-depleted cells, produced homologous results to
the RNA-seq data (Fig. 2a). Alterations in apoptotic genes are
common in pRB-depleted cells, and our multi-omics analysis
found these genes upregulated at the RNA but not the protein
level. To confirm these observations, we conducted RT-PCR for
cell death genes and found their RNA increased in pRB-depleted
cells (Supplementary Fig. 2F). Western blot analysis of candidate
proteins sensitive to pRB-depletion identified by Mass Spectro-
metry, highlighted the reproducibility of our data (Fig. 2b). To
determine how each of the changes in RNA and protein levels are
coordinated in pRB-depleted cells, we conducted a system-wide
analysis. The levels of RNA and protein were converted in log10
values from individual RNA-seq and proteomic replicates and
then compared. This analysis showed that alterations in the levels
of RNA, rather than protein, were the most significant between
control and pRB-depleted cells (Fig. 2c). We next investigated
how well RNA and protein changes are linked in each replicate.
From this, we found that transcriptional profiles of RB25 and
RB26 were very tightly correlated (compare RNA: RB25 vs. RB26)
(Fig. 2d) whilst the protein profiles also showed strong correla-
tions (compare Protein: RB25 vs. RB26) (Fig. 2d). However,
merging the RNA and protein datasets from either shRNA group
do not correlate well (compare RNA and Protein: RB25 vs. RB26)
(Fig. 2d). These results suggest that RNA changes upon RB-loss
are frequently not reflected at the protein levels in RPE1 cells. To
determine whether these changes were affected by codon bias or
rare amino acid composition, we analyzed the relative level of
each in the proteins altered by pRB-depletion. From this analysis,
we found that codon or amino acid biases are unlikely contribute
a
Deplete pRB or control by shRNA
b










GO term Score p-value




Cell migration 2.06 4.2*10-4
Downregulated RNA
GO term Score p-value
Extracellular matrix 6.13 2.6*10-7
Cell morphogenesis 1.56 0.004
Hormone Stimulus 1.5 0.016
Upregulated Protein
GO term Score p-value
Pentose Biosynthetic 45.89 0.018
Purine Salvage 45.89 9.7*10-4
ISG-15 conjugation 38.24 0.002
Glycosylation 20.4 1.5*10-8
Methionine Metabolism 18.36 1.7*10-4
Interferon Response 10.6 2.6*10-7
GO term Score p-value
Organelle organization 2.39 0.026




























Fig. 1 Profiling how pRB-depletion changes human RPE1 cells. a Schematic detailing experimental approach and western blot of pRB and Tubulin (TUB)
from RPE1 cells infected with DOX-inducible shRNAs targeting Firefly Luciferase (LUC) or pRB (RB-25 and RB-26). b Log2 fold-change of RNA changes in
RPE1 cells depleted of pRB (RB25 and RB26), Red dots are statistically significant. c Gene ontology analysis of upregulated mRNAs (Green box, enrichment
scores, and FDR p-values) and downregulated mRNAs (Red box, enrichment scores, and FDR p-values). d Graph of genes changed upon pRB-depletion
from RPE1 cells that are bound by E2F1 or E2F4/6 from ChIP data. e Log 2 Protein fold-change from RPE1 cells depleted of shRNAs targeting RB using
shRNA RB25 and RB26, Red dots are statistically significant. f Gene ontology analysis of upregulated proteins (Green box, enrichment scores, and FDR
p-values) and downregulated proteins (Red box, enrichment scores and FDR p-values).
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to these effects (Supplementary Fig. 3A, B). This analysis shows
that pRB-depletion causes complex alterations in both RNA and
protein levels and synthesis rates.
Metabolic changes are widespread in pRB-depleted cells. We
have previously described mitochondrial defects in Rb1-deleted
murine tissue23 and asked whether similar changes also occur in
human cells. Steady-state LCMS profiling of the panel of
RPE1 cells identified 35 metabolites (Fig. 3a) that were altered in
pRB-depleted cells (Supplementary Data 3). Many of these
changes affected metabolites in the glucose metabolism and
purine/pyrimidine biosynthetic pathways. In concordance with
previous reports, we observed a clear and consistent alteration in
mitochondrial processes in pRB-depleted human cells (Supple-
mentary Fig. 3C, D). To independently evaluate our results, we
tested the levels of cellular acidification, using ELISAs from DOX-
treated cells. From this analysis, we found elevated levels in pRB-
depleted cells (Supplementary Fig. 3E). To measure how pRB-
depletion changes the metabolic profile of different cell types, we
used pLKO.1 vectors and different sets of shRNAs to deplete pRB
from human BJ fibroblasts. As shown in Supplementary Fig. 3F,
shRNA-mediated pRB-knockdown resulted in highly repro-
ducible metabolite changes suggesting that these alterations are in
direct response to pRB-depletion. These changes were not seen in
cells with deletions in pRB homologs, Rbl1 and Rbl2 (Supple-
mentary Fig. 4A). To determine whether changes in mTOR
activity, caused by pRB-depletion, was contributing to this pro-
cess, we measured the phosphorylation levels of the mTOR target,
S6 kinase. These results showed mTOR levels are unchanged in
pRB-depleted cells (Supplementary Fig. 4B). To better understand
the associated metabolic consequences, we combined the meta-
bolic, and proteome profiles and looked for concerted patterns of
change in the merged data. We discovered that many of the
proteins and metabolites involved in the glucose metabolism
pathway are coordinately increased in pRB-depleted cells (Fig. 3b,
e (Red bars) and F, Red dots). The majority of these genes were
unchanged or decreased at the mRNA level (Fig. 3f, Red dots),
despite being directly bound by E2F1 (Supplementary Fig. 4C).
This suggests that the elevated protein levels may reflect increased
metabolite levels (Fig. 3b, e, f). In contrast, although multiple
TCA cycle metabolites were increased in pRB-knockdown cells
(Fig. 3b, e (Green bars), the proteins that catalyze these reactions
displayed reduced levels (Fig. 3b, f (Green dots)). Decreased
enzymatic activity, coupled with elevated amounts of metabolites,
are consistent with decreased movement through TCA cycle
previously described in pRB mutant cells23. Together, these
results describe an extensive pattern of metabolic reprogramming
of the glucose pathway and TCA cycle following pRB-depletion
from human cells33.
In a similar way, the combination of proteomic and metabolic
data revealed a consistent and extensive pattern of changes in purine
and pyrimidine metabolism in pRB-depleted cells, with both
synthetic pathways clearly elevated by pRB-knockdowns. The
profiles showed increased levels of multiple key components of
pathways leading to the production of nucleosides and nucleotides
(highlighted in blue and yellow in Fig. 3c, d). Concordantly,
metabolite profiling of pRB-depleted cells showed increased levels of
the purine and pyrimidine precursors detected in our analysis
(Fig. 3e, Blue bars), with the exception of dCDP and dCTP. This
systematic pattern of changes in enzyme levels was evident even
though many of the purine and pyrimidine genes were not
transcriptionally upregulated upon pRB-depletion (Fig. 3f, Blue
dots). This suggests that the increased protein levels reflect the
elevated activity of the synthetic pathways, rather than being solely a
consequence of increased transcription. Chromatin Immunopreci-
pitation (ChIP) of the activator E2F, E2F1, confirmed that several of
the purine and pyrimidine genes were bound by E2F1 (Supplemen-
tary Fig. 4D) but many of these were not transcriptionally
upregulated upon pRB-depletion (Fig. 3f, Blue dots). To exclude
the possibility that the activation of purine and pyrimidine
metabolism upon pRB-knockdown was a unique feature of
RPE1 cells or the pINDUCER11 system, we independently evaluated
pRBs role in purine and pyrimidine metabolism. By profiling
shRNA depleted human BJ fibroblasts, we identified widespread
changes in purine and pyrimidine metabolites (Supplementary
Fig. 3F). Taken together, these findings provide strong evidence that
the purine/pyrimidine pathway is strongly upregulated in pRB-
depleted cells. Such changes are consistent with increased replication
and/or DNA damage.
Metabolic changes identified in pRB-depleted RPE1 cells are
also present in RB1−/− Retinoblastoma. While RPE1 cells are a




















































































































































Fig. 2 Combining profiles to determine the effect of pRB-depletion. a Relative RT-PCR levels of RB1, ARL14, SERPINA9, IL18, TPI, and PGK1 from RB-25/
26 without DOX addition (WT) and plus DOX (RB-KD) (**p < 0.01, ***p < 0.001). n= 3 biological replicates and a total of 9 technical replicates. Error bars
represent standard deviations from the replicates. b Western blots of pRB, WARS, ATP5E, ADP-GK and ACTIN from control and RB1−/− RPE1 cells. c Heat
maps and statistical analysis of RNA and protein changes in pRB-depleted cells. d Correlations comparing RNA and protein changes between replicates,
highlighting the poor correlations between RNA and protein.
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good model for pRB research, we next wanted to investigate
whether these changes are also seen in RB1-mutant human
tumors. To assess this, we compared the RNA and protein
changes seen in RPE1 cells with the properties of RB1−/−
human Retinoblastomas. We utilized previously published
RNA-seq34 and proteomic35 data from normal retinal tissue
and Retinoblastoma tumors to investigate how the RNA and
protein levels of E2F target genes were changed. In agreement
with our RPE1 data, we find poor correlations between relative
RNA and protein changes in many E2F target genes from these
tumors (Fig. 4a). To independently determine the RNA
expression changes of E2F target genes in Retinoblastoma, we
used RT-PCR to measure the levels of a subset of E2F targets.
By analyzing this independent tumor cohort, we find strong
upregulation of E2F target genes in these tumors (Supple-
mentary Fig. 4E, F). We then expanded this analysis to ask
whether the protein levels of the metabolic pathways were also
altered. From this, we found that much like our RPE1 cells,
TCA cycle components were lower in RB1−/− mutant tumor
samples (Fig. 4b), whilst the proteins necessary for enhanced
purine and pyrimidine biosynthesis were elevated (Fig. 4c). We
next independently tested whether we would detect these pro-
tein changes using western blot analysis. To do this, we mea-
sured the levels of TCA protein, Citrate Synthase (CS), in six
Retinoblastoma tumor samples and three normal retinal con-
trols. In agreement with our proteomic data, we find reduced
levels of the CS protein in each of the tumor samples (RB1-6)
compared to the controls (Ret1-3) (Fig. 4d). These results
suggest that our profiles of pRB-depleted RPE1 cells mirror key
changes present in RB1−/− Retinoblastoma tumors.
Proteomics changes in pRB-depleted cells are conserved in RB1−/−
mouse tissue and human tumors. To determine whether changes in
pRB-depleted cells are also seen in complex tissue and adult human
tumors, we compared the proteome of pRB-depleted RPE1 cells to
those from Rb1-mutant tissue and human SCLC tumors. For this, we
first examined the correlation between protein changes in pINDUCER
pRB-depleted RPE1 cells to Rb1-deleted murine tissue23. From this, we
identified a strong correlation (r= 0.51) between protein alterations in
pRB-depleted RPE1 cells relative to both Rb1−/− lung (Fig. 5a) and
colon (Fig. 5b) mouse tissue. The reproducibility of protein changes in
experimental models of pRB-depletion, suggests that these models
provide important and conserved information on pRB’s role in cellular
regulation. We then expanded this analysis to determine how these
profiles compared to published proteomic datasets from human
RB1−/−; TP53−/− SCLC tumors36. By comparing statistically sig-
nificant differences from pRB-depleted cells to SCLC tumors, we find a
clear separation of proteomic signature between pRB-knockdown
(+DOX) relative to pRB-positive (−DOX) cells (Fig. 5c). We then
asked whether proteomic changes (Fold-change > 2, p-value > 0.05) in
SCLC tumors were also present in our RPE1 cells. As shown in Fig. 5d,
these changes are also seen in our cells, suggesting that our RPE1 based
on pRB-depletion is able to capture proteomic events seen in RB1−/−
tumors. From these results, our data suggest that RPE1 accurately
models how pRB-knockdown changes the biology of cells and provides
a basis for tumorigenesis.
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Fig. 3 Glucose and purine/pyrimidine metabolism changes in pRB-depleted cells. a Heat map of metabolic changes in LUC, RB25, and RB26 DOX-
treated/DOX-untreated with fold changes and adjusted p-value calculations. b Pathway analysis of Glucose metabolism and TCA cycle genes upon pRB-
loss. Upregulated metabolites highlighted in yellow, downregulated metabolites shown in green, protein increased in pRB-depleted cells shown in blue and
proteins decreased in pRB-depleted RPE1 cells shown in red. c Pathway analysis of Pyrimidine metabolism upon pRB-loss. Upregulated metabolites
highlighted in yellow, protein increased in pRB-depleted cells shown in blue. d Pathway analysis of Purine metabolism upon pRB-loss. Upregulated
metabolites highlighted in yellow, protein increased in pRB-depleted cells shown in blue. e LCMS data showing relative (pRB (−)/pRB (+)) metabolite
changes from RPE1 cells for Glucose pathway metabolites (red bars) and Purine/Pyrimidine metabolites (blue bars) (*p < 0.01). n= 4 biological replicates
and a total of 8 technical replicates. Error bars represent standard deviations from these replicates. f RNA and Protein changes in glucose metabolism
genes (red circles), purine and pyrimidine metabolism genes (blue circles), and TCA cycle genes (green circles) in RPE1 cells depleted of pRB.
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Identifying sensitivities to proteomic changes. Although this
data provides molecular details of how pRB-depletion alters cells,
we wanted to determine which of these changes are passenger
events and which sustain the growth of cells in vivo. To bypass
the high levels of functional redundancy in human cells, we used
an established E2f1-RNAi Drosophila eye model to determine
how the depletion of homologs of each of these upregulated
proteins modified E2f1-RNAi phenotypes. Using the Glass Mul-
tiple Reporter (GMR) GAL4 driver, we ectopically expressed a
UAS-E2f1 construct to deplete E2f1. GMR-E2f1-RNAi alters the
progression of the morphogenic furrow across the developing eye
disc, resulting in aberrant proliferation, metabolism5, and
apoptosis24. These effects have previously been shown to be
rescued or exacerbated by changes in pRb, E2f, and Cdk family
members24. We selected this system, as GMR-mediated depletion
of E2f1 results in a strong overgrowth phenotype (Fig. 6a) that is
highly modifiable, reproducible, and enables straight-forward
screening. In contrast, GMR-Rbf1-RNAi results in a rough eye
phenotype that is harder to screen. Importantly, screens con-
ducted in both settings, produce highly similar results. We then
tested how RNAi-mediate depletion of the Drosophila homologs
of 354 upregulated proteins in pRB-depleted RPE1 cells affected
the GMR-Gal4/UAS-E2f1-RNAi rough eye phenotype. From this
analysis, we identified 28 genes that when knocked down were
able to suppress the E2f1-RNAi phenotype (Fig. 6b). Similarly, we
found 30 genes that when depleted could enhance or expand the
area of the eye affected by the E2f1-RNAi phenotype (Fig. 6c).
Each of these modifiers were independently test against control
GFP-RNAi lines and found to have no effect on normal eye
development. Analysis of these results identified a number of
metabolic and cell cycle genes as important for E2f1-RNAi phe-
notype (Fig. 6d). Pathway analysis of enhancers of the E2f1-RNAi
phenotypes was linked to TNF and EGFR signaling and the p53
transcription factor (Supplementary Fig. 5A). In contrast, the
suppressors were functionally linked to HSP90 and CCND1
activity (Supplementary Fig. 5B). To evaluate how these processes
affect the growth of RB1−/− RPE1 human cells, we used small
molecular inhibitors that alter glucose (2-Deoxy-D-Glucose,
2DDG) or serine (O-phospho-DL-serine, OPDLS) metabolism.
These pathways were selected as glucose pathways manipulations
exacerbated Drosophila E2f1-RNAi phenotypes, in contrast,
changes to serine metabolism suppressed the phenotypes. Wild
type and RB1−/− RPE1 cells were treated with vehicle control
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Fig. 4 Comparing the effect of pRB-depletion in RPE1 cells to RB1 mutation in Retinoblastoma tumors. a Comparison of the RNA and protein levels of
E2F target genes in RB1−/− Retinoblastoma tumors. b Relative TCA cycle protein levels in Retinoblastoma tumor samples compared to normal retina. n= 5
independent tumors and 5 retina controls. Error bars represent standard deviations from these replicates. c Relative purine and pyrimidine protein levels in
Retinoblastoma tumor samples compared to normal retina. n= 4 independent tumors and matched controls. Error bars represent standard deviations from
these replicates. d Western blots of the TCA cell cycle gene, CS, and ACTIN, from six Retinoblastoma tumors (1–6) and three retinal samples (a–c). Graph
represents western blot quantification from three independent assays. Error bars represent standard deviations from these replicates.
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measured. As shown in Fig. 6e, RB1−/− cells are highly sensitive
to OPDLS treatment, while being resistant to 2DDG. This data
shows that some of the proteomic changes in pRB-depleted cells
have conserved roles in maintaining cells with de-regulated E2F
activity in Drosophila and human cells.
Discussion
Despite the great clinical need, finding therapeutic strategies to
target pRB-depleted cancer cells has proved to be a difficult
challenge. A major obstacle is that there is surprisingly little
information about the ways that the inactivation of pRB changes
the molecular characteristics of non-tumorigenic human cells.
Previous studies, using Rb1mutant mouse tissue, have shown that
the current, transcription-centric view of the effects of pRB loss is
incomplete, but proteomic profiling of heterogeneous mouse
tissues provided only a low-resolution picture of the changes
caused by the mutation of Rb123. Here, we report quantitative
measurement of changes to the metabolome, transcriptome, and
proteome that occurred when pRB is removed from a homo-
genous diploid non-transformed human cell line. Collectively,
this data provides a detailed picture of the pathways affected by
pRB loss. Although pRB is often categorized in simple terms as a
cell cycle protein or a transcriptional repressor, this data builds on
other studies to illuminate the way that pRB loss has broad cel-
lular consequences that impact diverse cellular pathways.
We highlight three features of pRB-depleted cells that are
evident when the different sets profiles are viewed together. First,
there are many examples where changes seen in one type of data
are reinforced by changes in another. For example, pRB-depletion
increased the levels of a suite of enzymes involved in purine and
pyrimidine synthesis. These changes were accompanied by
increases in the levels of nucleotides and nucleosides, suggesting a
concerted increase in their synthesis. As pRB-depleted cells and
pRB-deficient cancer cells have altered DNA replication rates, it is
likely that higher nucleoside and nucleotide generation is essential
to sustain these processes. In a similar way, systematic increases
in the levels of glycolytic enzymes and the levels of the associated
metabolites clearly demonstrate an upregulation of glycolytic
pathway in pRB-depleted cells. These results strongly support
recent observations of reduced mitochondrial function in pRB-
depleted cells. Our data and that from a number of other groups
strongly suggest that pRB-loss begins the metabolic reprogram-
ming of cells and mitochondrial mis-regulation. After just 6 days
of pRB-depletion, we find that multiple mitochondrial pathways
including key metabolic and nucleoside producing reactions are
directly altered. Research from a number of different models have
demonstrated that pRB-depletion results in mitochondrial
changes and our data suggest that these changes are apparent
within days of pRB-loss. More work is needed in additional cell
lines and at different time points to understand how metabolic
flux and mitochondrial activity are altered by pRB-deficiency.
However, these studies provide a platform expanding these
important questions into different models and cancer contexts.
Second, each type of profiling provides a different perspective
on the changes in a pRB-depleted cell. In part, this is because each
profiling approach has limitations that make it easier to detect
changes in some processes, but not others. For example, low
abundance proteins are difficult to quantify by mass spectro-
metry, and the insights provided by metabolic profiling are lim-
ited by the number and variety of standards used to identify
peaks. Transcription profiles of RB-depleted cells emphasize
changes in E2F targets, proteome profiles highlight changes in
mitochondrial proteins and other pathways, while the metabolic
profiles show changes in glucose metabolism and nucleotide
synthesis. Each of these changes are genuine consequences of pRB
inactivation and it is the integration of the different phenotypes

















Fig. 5 Proteomic changes in RB-depleted RPE1 cells are also present in Rb1−/− murine tissue and SCLC tumors. a Graph and correlation of protein
changes in pRB-depleted RPE1 cells relative to Rb1−/− murine lung tissue. b Graph and correlation of protein changes in pRB-depleted RPE1 cells relative to
Rb1−/− murine colon tissue. c Heat map of proteins altered in pRB-depleted RPE1 cells compared to the proteome of SCLC tumors. d Heat map of
upregulated and statistically significant proteins SCLC tumors compared to pRB-depleted cells.
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Third, perhaps the most curious and unexpected insights stem
from differences between the datasets. It is important to appreciate
that while some of the transcriptional changes resulting from
pRB-depletion are accompanied by a measurable change in protein
levels, many do not. Indeed of the most striking features of this
analysis are the differences in pathways changed at the mRNA and
protein level. Our Gene Ontology profiling of each dataset found
limited overlap between mRNA and protein changes and merging
this information suggested that pRB-loss results in a complex
transcriptional and proteomic response. In particular, the direct E2F
target genes that we had hypothesized to be increased at the mRNA
and protein levels, can actually be sub-divided into multiple dif-
ferent RNA: protein categories. The majority of the traditional E2F
target genes are transcriptionally upregulated but only a subset these
genes are also increased at the protein levels. These observations
suggest that many E2F targets genes are subject to post-
transcriptional or translational control. Interestingly, the factors
that are strongly elevated at the mRNA but not the protein level
show longer coding sequences, and have longer 5′UTRs and 3′
UTRs (Supplementary Fig. 5C–E). These results show that post-
transcriptional regulation of E2F-induced mRNAs is important, and
likely buffers the effects of E2F activation on the levels of protein
required for cell proliferation and apoptosis.
Finally, by testing which of these upregulated pathways are
important for the growth and survival of Drosophila models and
RB1−/− human cells, our analysis has identified important pro-
teomics events. Perhaps unsurprisingly, we find that cell cycle
components act to both enhance and suppress in vivo phenotypes
as these cells clearly have altered cell cycles, proliferation, and
differentiation programs. The largest and most striking collection
of genes that function to drive these phenotypes are metabolic,
and have diverse roles in nucleotide generation and TCA cycle
progression. This is likely due to elevated metabolic demands of
the cells and the need for high levels of building blocks necessary
for DNA replication, DNA repair, and growth. This data from
Drosophila models accurately represents metabolic sensitivities as
inhibiting these pathways in RB1−/− human cells, significantly
slows the growth and triggers widespread apoptosis. Many of
these change make sense based on how we understand pRB-
depletion alters the growth profile of human cells, however the
role of many of these upregulated but essential genes remains
untested or unknown. Key factors regulating Ribosome assembly,
Vacuole transport and cell adhesion are very strong modifiers of
the E2f1-RNAi phenotype, suggesting that widespread cellular
changes are important for responding to both direct and indirect
changes driven by pRB-depletion and E2F-deregulation.
Given that pRB and E2F are involved in the temporal control
of gene expression, we appreciate that the absence of a measur-
able difference in the overall levels of a protein in a population of
cells does not necessarily mean that the transcriptional changes
are unimportant. However, we note that the data described in
these experiments show the depletion of pRB does lead to sta-
tistically significant changes in levels of hundreds of proteins, and
many of these changes are not evident in the transcript data. The
proteins altered in level by the depletion of pRB function in
diverse cellular processes and we hope that further studies of
these changes may reveal features of the pRB-depleted state that
are vulnerabilities and that can be targeted therapeutically.
+hyx RNAi    +cg6907 RNAi    +ari2 RNAi
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Fig. 6 Identifying the essential proteins within the upregulated protein group using in vivo models. a Representative Scanning Electron Microscopy
(SEM) images of Drosophila eyes from Wild type and GMR-E2f1-RNAi animals. White bar = 100 µm. b Representative Scanning Electron Microscopy
(SEM) images of Drosophila eyes from genes that when depleted can suppress the GMR-E2f1-RNAi phenotype. White bar = 100 µm. c Representative
Scanning Electron Microscopy (SEM) images of Drosophila eyes showing seven genes that when depleted can enhance the GMR-E2f1-RNAi phenotype.
White bar = 100 µm. d Schematic detailing the number of modifiers identified in the GMR-E2f1-RNAi genetic screen. e Relative cell number of wild type or
RB1−/− RPE1 cells treated with vehicle (DMSO), 2DDG and OPDLS (*p < 0.05). n= 3 independent experiments. Error bars represent standard deviations
from these replicates.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02495-2
8 COMMUNICATIONS BIOLOGY |           (2021) 4:977 | https://doi.org/10.1038/s42003-021-02495-2 | www.nature.com/commsbio
Methods
Antibodies. pRB antibody (1:1000): Abcam (ab181616), ATP5E (A-11) (1:500):
Santa Cruz Biotechnology, Inc. (sc-393695), TrpRS (C-7) (WARS) (1:500): Santa
Cruz Biotechnology, Inc. (sc-374401), ADPGK (AA40) (1:500): Santa Cruz Bio-
technology, Inc. (sc-100751), β-Actin (1:1000): Cell Signaling Technology (#4967),
CS (1:1000): Sigma, SAB 2701077, p-pRB (Ser807/811) (1:1000): CST (#8516 S),
RBL1 (1:500): Santa Cruz (sc-250), RBL2 (1:500): Santa Cruz (sc-374521), S6
(1:1000): CST (#2217) and S6K Ser235/236 (1:1000): CST (#4858).
Cell culture. RPE1, BJ, and murine 3T3 cells were grown DMEM containing 5%
(tetracycline free) FBS and Glutamine under standard culturing conditions. RPE1
and BJ cells are both from ATCC, and were confirmed using Short Tandem Repeat
(STR) profiling. The 3T3 cells were provided by the Dyson group and confirmed by
STR profiling. Firefly Luciferase and RB depletion cells were grown in the media
described above supplemented with 4 µg/ml of Doxycycline for 3 days before being
split and grown in new DOX-supplemented DMEM/FBS for a further 3 days. Non-
DOX-treated cells were grown using the same protocol without the addition
of DOX.
Plasmids and generation of pINDUCER11 stable lines. The pINDUCER11
plasmids targeting Firefly Luciferase and pRB were kind gifts from Steven
Elledge28. Virus was generated using standard lentiviral protocols. To produce
stable lines, RPE1 cells were independently infected with lentivirus containing
either pRB or Firefly Luciferase targeting pINDCUER11. Three days post-infection,
cells were trypsinized and sorted via live Fluorescence-activated cell sorting (FACS)
for GFP positivity. Strongly GFP-positive cells were collected and used to generate
independent pooled stable cell lines.
FACS. Cells were labeled briefly with 20 µM Edu (Click Chemistry Tools) for 2 h,
incubated at 37 °C, fixed with 3.7% formaldehyde for 15 min, permeabilized in
0.5% Triton-X 100 in PBS. Each step was followed by a wash using 3% BSA in PBS,
centrifuged on a table-top centrifuge at 2000g for 1 min. The cells labeled with Edu
were incubated in the Click-IT reaction mix (100 mM Tris-Cl (pH7.5), 3 mM
CuSO4, 50 mM Ascorbic Acid, 2.5 µM Alexa-647 Azide) for 30 min in dark. The
cells in specific cell cycle stages were detected using 3 µM (892 ng/ml) DAPI in PBS.
All samples were analyzed in triplicates using BD LSR-Fortessa flow cytometer and
BD FACS-Diva 8.0.1 software.
RNA sequencing and differential expression analysis. Total RNA was extracted
from cells using Trizol. Total RNA Sequencing libraries were prepped using the
TruSeq Stranded Total RNA kit including rRNA depletion with Ribo Zero Gold kit
(Illumina). 250 ng of RNA were used for library preparation following the sup-
plier’s instructions, including 10 cycles of PCR amplification. The quality of the
library was assessed by TapeStation (Agilent) using the high sensitivity D1000
reagents. Library was quantified with Qubit (Thermofisher) and paired-end
sequenced (41 cycles each way) using Nextseq 500 High output v2 kit (Illumina) on
the NextSeq500 at the MGH Cancer Center.
Files containing RNA sequencing reads were adaptor and quality-trimmed
using TrimGalore-0.6.0. Bowtie2 (version 2.2.9) was used to removing
contaminating reads from ribosomal RNA and transfer RNA37–39. The trimmed
and contamination-filtered reads were mapped to the hg38 genome (GENCODE
Release 31) using STAR aligner version 2.5.2a and a counts matrix was obtained
using the ‘Gene Counts’ option40. The DESeq2 (version 1.22.2) package was used to
perform a differential expression analysis using R version 3.5.341. The Ensembl IDs
were converted to gene symbols and names using the org.Hs.eg.db package (version
3.7.0). FPKMs were calculated using the fpkm function from DESeq2 using lengths
determined via the feature Counts function in the Rsubread package (version
1.32.4) using R version 3.5.042. The data are available at GEO accession number:
GSE140383.
Gene feature length and codon analysis. Gene feature lengths and amino acids
compositions were extracted from the RefSeq hg19 annotation, and averaged per
gene in case of multiple isoforms. Enrichment/depletion of amino acids are cal-
culated as log2 of the average percentage of the amino acid in the RuPn or RnPu set
divided by the average percentage of the amino acids in all genes set. The
Kolmogorov-Smirnov test was used to calculate p-values.
Proteomics. A 10 cm dish containing 85–90% confluent RPE1 cells containing
different pINDUCER11 construct +/- DOX were collected in duplicate for pro-
teomics. Multiplexed quantitative mass spectrometry-based proteome mappings
were done in duplicate using TMT-10 plex reagents and the SPS-MS3 method on
an Orbitrap Fusion mass spectrometer (Thermo Scientific)31,43. As described
previously43, disulfide bonds were reduced, free thiols were alkylated with iodoa-
cetamide; proteins were purified by MeOH/CHCl3 precipitation and digested with
Lys-C and trypsin, and peptides were labeled with TMT-10plex reagents (Thermo
Scientific)31. Labeled peptide mixtures were pooled and fractionated by basic
reversed-phase HPLC as described previously43. Twelve fractions were analyzed by
multiplexed quantitative proteomics performed using the Simultaneous Precursor
Selection (SPS) based MS3 method on an Orbitrap Fusion mass spectrometer
(Thermo Fisher Scientific) coupled to an Easy-nLC 1000 (Thermo Fisher Scientific)
with auto sampler30–32. Peptides were separated on a micro capillary column
(inner diameter, 100 µm; outer diameter, 360 µm; length, 30 cm, GP-C18, 1.8 µm,
120 Å, Sepax Technologies). Peptides were eluted with a linear gradient from 11 to
30 % ACN in 0.125 % formic acid over 165 min at a flow rate of 300 nL/min. The
Orbitrap Fusion was operated in data-dependent mode, with a survey scan per-
formed over an m/z range of 500–1200 in the Orbitrap with a resolution of 6 × 104,
automatic gain control (AGC) of 5 × 105, and a maximum injection time of 100 ms.
The most abundant ions detected in the survey scan were subjected to MS2 and
MS3 experiments to be acquired in a 5 sec experimental cycle. For MS2 analysis,
doubly charged ions were selected from an m/z range of 600–1200, and triply and
quadruply charged ions from an m/z range of 500–1200. The ion intensity
threshold was set to 5 × 104 and the isolation window to 0.5m/z. Peptides were
isolated using the quadrupole and fragmented using CID at 30 % normalized
collision energy at the rapid scan rate using an AGC target of 1 × 104 and a
maximum ion injection time of 35 ms. MS3 analysis was performed using syn-
chronous precursor selection (SPS)30,31. Up to 10 MS2 fragment ions were
simultaneously isolated and subjected to MS3 analysis with an isolation window of
2.5m/z and HCD fragmentation at 55 % normalized collision energy. MS3 spectra
were acquired at a resolution of 6 × 104 with an AGC target of 1 × 105 and a
maximum ion injection time of 100 ms. The lowest m/z for the MS3 scans was set
to 110. An identical bridge sample from pooling all tryptic digests was added to
each of the three TMT-pools analyzed for this study to allow the comparison of
proteome profiles across all samples32. MS2 spectra were assigned using a
SEQUEST-based proteomics analysis platform44. The protein sequence database
for matching the MS2 spectra was based on the human uniprot protein sequence
database. Peptide and protein assignments were filtered to a false discovery rate of
< 1 % employing the target-decoy database search strategy45 and using linear
discriminant analysis and posterior error histogram sorting44. Peptides with
sequences contained in more than one protein sequence from the UniProt database
were assigned to the protein with most matching peptides44. We extracted TMT
reporter ion intensities as those of the most intense ions within a 0.03 and the
window around the predicted reporter ion intensities in the collected MS3 spectra.
Only MS3 with an average signal-to-noise value of larger than 20 per reporter ion
as well as with an isolation specificity30 of larger than 0.75 were considered for
quantification. A two-step normalization of the protein TMT-intensities was per-
formed by first normalizing the protein intensities over all acquired TMT channels
for each protein based on the median average protein intensity calculated for all
proteins. To correct for slight mixing errors of the peptide mixture from each
sample a median of the normalized intensities was calculated from all protein
intensities in each TMT channel and the protein intensities were normalized to the
median value of these median intensities. Mass spectrometry RAW data are
accessible through the MassIVE data repository (massive.ucsd.edu) under the
accession number MSV000084736.
Proteomics analysis. Differential protein expression between pRB+ and pRB-
depleted proteomes was calculated using a T-test. The Benjamini-Hochberg mul-
tiple hypothesis correction was applied to calculate corrected p-values (FDR).
Differential expression of proteins between pRB+ and pRB− samples was con-
sidered significant with an FDR < 10% and a minimum absolute log2 FC <−0.5
and FC > 0.5. To generate pRB-loss data, we first calculate protein changes in FF-
DOX and FF+DOX samples as this represents non-specific or DOX-mediated
changes in the proteome. These proteins were removed from both the RB25 and
RB26 data. We then compared the proteome of FF-DOX, RB-25-DOX, and RB26-
DOX and found no statistically significant differences. These normalized data were
then used to identify proteomic changes after pRB-loss from RB25 and
RB26 separately.
Harvesting human cells for LC-MS/MS. To harvest intracellular metabolites,
wells were washed once with 150 mM sodium chloride solution. Wells were
aspirated and intracellular metabolites from cells on dry ice by scraping cells from
each well into 500uL of chilled Acetonitrile/methanol/water (40/40/20) (Sigma,
ACS grade), samples were quickly vortexed and placed on dry ice to freeze. A series
of 3 freeze/thaw cycles were performed. The cellular lysate was clarified at 4 °C with
a spin of 21k × g for 10 min. Clarified lysate was transferred and then lyophilized
and snap frozen in liquid nitrogen. Prior to mass spectrometry analysis, samples
were re-suspended using 20 µL HPLC grade water.
Metabolite LC-MS/MS analysis. LC-MS/MS analysis was done as previously
described5,46. Briefly, analysis was performed on a 5500 QTRAP hybrid triple
quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC HPLC
system (Shimadzu). For analyses of metabolite pools 10 µL of each sample was
injected and analysis was done using selected reaction monitoring (SRM) of a total
of 258 endogenous water-soluble metabolites. As some metabolites were targeted in
both (+) and (−) ion mode, a total of 289 SRM transitions due to ion mode
switching were analyzed. For 13 C labeled experiments, specific SRMs were con-
structed based on predicted 13 C incorporation patterns. Desired ions were pro-
duced using an ESI voltage of +4900 V in (+) ion mode and −4500 V in (−) ion
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mode. Between 9 and 12 data points were acquired per detected metabolite using a
dwell time of 3 ms per SRM transition and a total cycle time of 1.55 s. Sample
delivery to the MS was done under normal phase chromatography using a 4.6 mm
i.d × 10 cm Amide Xbridge HILIC column (Waters Corp.) at 300 ml/min. Gra-
dients were run starting from 85% buffer B (HPLC grade acetonitrile) to 42% B
from 0 to 5 min; 42% B to 0% B from 5 to 16 min; 0% B was held from 16 to 24
min; 0% B to 85% B from 24 to 25 min; 85% B was held for 7 min to re-equilibrate
the column. Buffer A was comprised of 20 mM ammonium hydroxide/20 mM
ammonium acetate (pH= 9.0) in water: acetonitrile (95:5). Peak areas from the
total ion current for each metabolite SRM transition were integrated using Mul-
tiQuant v2.0 software (AB/SCIEX).
Glycolysis assay. Glycolysis Assay (Abcam #ab197244) was performed to measure
extra-cellular acidification as a read-out for lactate metabolite. 5 × 104 cells were
seeded per sample on a 96-well black plate and incubated in a 37 °C, 5% CO2
incubator overnight for the cells to attach. The next day, the glycolysis assay was
performed as mentioned in the manufacturer protocol. The fluorescent reading was
obtained on SpectraMax microplate reader using excitation and emission wave-
lengths of Ex/Em= 380/615 nm.
Gene ontology analysis. Differentially expressed genes and proteins were mea-
sured for enriched gene ontology terms using DAVID website tool (https://david.
ncifcrf.gov/)47–49. Genes and proteins with statistically significant level changes
were mapped to different gene ontology pathways using stringent program settings.
Ingenuity pathway analysis (IPA). Core expression analysis was performed using
the commercial software Ingenuity Pathway Analysis (Ingenuity™ Systems; IPA;
http://www.ingenuity.com) tool. The analysis performed was based on log ratio of
protein expression in pRB-KD/WT. The input list was normalized with the
reference gene set from Ingenuity Knowledge Base (Genes only). Graphical
representations of the networks containing direct relationships were generated for
both enhancers and suppressors obtained from the fly screen.
Chromatin immunoprecipitation (ChIP). ChIP was performed using protocols
and reagents from the Simple Chip Enzymatic Chromatin IP Kit (CS 9003).
Proliferating RPE1 cells were cross-linked in 1% formaldehyde, rocking for 10 min
at room temperature. Crosslinking was quenched with glycine at a final con-
centration of 0.125M, rocking at room temperature for 5 min. Plates were washed
twice with ice cold PBS, scraped into a new tube, and pelleted by centrifugation at
350 g for 5 min. The supernatant was removed and pellet was processed according
to the manufacturer’s protocols. Chromatin was allowed to incubate with 5 µg of
either mouse anti-E2F1 (EMD Millipore 05–379) or normal mouse IgG (Santa
Cruz) at 4 °C overnight with rotation. 8 equivalents of beads were added to
immunoprecipitate the antibody-bound chromatin. After elution and reversal of
crosslinks, chromatin was purified by precipitation with ethanol overnight at −20 °
C. Chromatin concentration was determined using a Qubit Fluorimeter and a
Qubit dsDNA High Sensitivity Kit (Thermo Fisher Q32854). Real-time qPCR was
performed using Fast Start Universal SYBR Green Master Mix with Rox (Roche)
using the Applied Biosystems Step One Plus system. 100 ng of input DNA and 12.5
ng of IP DNA were added to each well. Primer sequences are list below (Table 1).
Each ChIP was conducted in biological and technical triplicates and the data
included within the paper represent means and standard deviations of these
reactions.
ChIP primers.
RNA isolation, cDNA synthesis, and quantitative RT-PCR. RNA was harvested
from RPE1 cells, Wild type, and Rb1−/− MEFs using the Qiagen RNaeasy minikit
as per the manufacturer’s instruction. From these extractions, 400 ng of RNA from
each cell line was used to generated cDNA was prepared using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems) according to the manu-
facturer’s protocol. The expression of the specified target genes was quantified by q-
RT-PCR using Fast Start Universal SYBR Green Master with ROX (Roche) and was
normalized to the expression of β-actin and normal samples. The primers used for
the qRT-PCR reactions are list below and each reaction was conducted in biological
and technical triplicates and the data presented represents means and standard
deviations from these reactions. All q-RT-PCR experiments were performed using
Roche SYBR green master mix under the following cycling conditions: Initial
denaturation – 95 C (10 mins); 95 C (15 s), 60 C (1 min) for 40 cycles; 95 C (15 s),
60 C (1 min), 95 C (15 s) for melt curve.
RT-PCR. RNA was extracted using Trizol reagent and 250 ng of RNA was used to
prepare cDNA. Reverse transcription was performed as mentioned in the manu-
facturer protocol using Applied Biosystems High-Capacity cDNA Reverse Tran-
scription Kit. The relative expression of the targets mentioned was calculated using
Ct values obtained from performing q-RT-PCR using Fast Start Universal SYBR
Green Master with ROX (Roche) and was normalized to the control sample. All
experiments were performed in at least triplicates, unless mentioned otherwise.
Custom primers were designed (Table 2).
Comparison between RPE1, murine, and SCLC proteomics. We compared our
proteomics results from the doxycycline-dependent inducible knockdown of RB (p
< 0.05 and log2 FC > 0.3785) to previously published proteomics results from
murine lung and colon samples from a pRB loss study23, as well as a previously
published small cell lung cancer study (SCLC)36. We overlapped significant results
from our doxycycline results with lung or colon proteins with a log FC > 0.3785
and with the same direction fold-change. These results in turn were overlapped
with the previously identified SCLC-specific proteins.
Retinoblastoma protein dataset. The dataset from the proteomic profiles of seven
Retinoblastoma tumors and three normal retinal tissues was downloaded35 and the
average of each protein level from the tumors normalized to retinal controls35. We
overlapped significant results from our doxycycline results with proteins with a log
FC > 0.3785 and with the same direction fold-change. Protein changes in Reti-
noblastoma tumors were normalized to proteins levels in control Retinal tissue.
Retinoblastoma RNA dataset. The RNA profiles of Retinoblastoma tumor and
normal retinal samples were downloaded34. Files containing RNA sequencing reads
were adaptor and quality-trimmed using TrimGalore-0.6.0. Bowtie2 (version 2.2.9)
was used to removing contaminating reads from ribosomal RNA and transfer
RNA37–39. The trimmed and contamination-filtered reads were mapped to the
hg38 genome (GENCODE Release 31) using STAR aligner version 2.5.2a and a
counts matrix was obtained using the ‘Gene Counts’ option40. The DESeq2 (ver-
sion 1.22.2) package was used to perform a differential expression analysis using R
version 3.5.341. The Ensembl IDs were converted to gene symbols and names using
the org.Hs.eg.db package (version 3.7.0). FPKMs were calculated using the fpkm
function from DESeq2 using lengths determined via the feature Counts function in
the Rsubread package (version 1.32.4) using R version 3.5.042. RNA changes in
Retinoblastoma tumors were normalized to RNA levels in control Retinal tissue.
Western blotting from retinoblastoma tumors and retinal tissue. The present
study was approved by the institutional ethics board and conducted at Medical
research foundation and Vision research foundation, Sankara Nethralaya, India
with Ethics No. 247-2011-P. Control retinas from cadaveric people were collected
Table 1 Primers used for ChIP in this study.
hMcm3p ChIP F GCGCGAAAACTTCCGAACTC
hMcm3p ChIP R CAGTCGCTAGTCCGACCTCA
hAPCp ChIP F TGGATGAGGCCCTCTGTTAGA
hAPCp ChIP R GCAGCACCCTGTGAACATCT
hADSLp ChIP F TGTAGCGCGGCTAAGTAACG
hADSLp ChIP R GACTTCCTTCACGCGGTCTC
hADSSp ChIP F CCACTCCCGTGCAAACCTC
hADSSp ChIP R TTGAAAGCGAGAGGTAGAGCG
hTIP1p ChIP F CTTCGTTGGGGGAAACTGGA
hTPI1p ChIP R CGAGGGCTTACCGGTGTC
hLDHA ChIP F GTGCATTCCCGGTACGGTAG
hLDHA ChIP R GAAAGCGGCTCCTACACCTC
hLDHB ChIP F TCTGTAACAGTCGTGCGGAG
hLDHB ChIP R AGGCGGTACTCGGATTTCCA
hOASL ChIP F CAGAAACTCCTCCACGGTCC
hOASL ChIP R ATATATCTGCCCAGCAGCGG
hWIBGPYM1p ChIP F ACTCGCCAATAATCCGGTCC
hWIBGPYM1p ChIP R AACAGTTGCTGAAATGGGCG
hFTDSJD2p ChIP F AAAGGCCCACCTCACCTAGA
hFTDSJD2p ChIP R AGGGACCTCAGTCTTCCCTC
hSOD1p ChIP F TAAAGTAGTCGCGGAGACGG
hSOD1p ChIP R TTCGTCGCCATAACTCGCTA
hCTPS1p ChIP F GTCGCTGACGGGAGGATCT
hCTPS1p ChIP R CGCCCCTGATTGGTAGGAG
hALDOA N ChIP F TGGCCGGAGATACATCCAAG
hALDOA N ChIP R CCTCATCAGATGCCGGACG
hPPAT R ChIP F TGAGTAACAGGGATCCGGGC
hPPAT R ChIP R CGAGGCAGTAAAGTTCGGGG
hIMPDH2 ChIP F CTGGGCCGCGCCAATATAAA
hIMPDH2 ChIP R ATACGCATGCGCTGTTTCTTC
hALDOA H ChIP F2 TGGGGAGGGATCGTGTTCTC
hALDOA H ChIP R2 TTTCCTTTACGAGGAGCGGG
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from C.U. SHAH eye bank, Sankara Nethralaya. Tumor tissues were collected with
informed consent from the parents/guardians of the patient. The Tumor (N= 6)
and Retina (N= 3) tissues were lysed in 1X RIPA buffer (Thermo Scientific, Cat
no: 89900) along with Protease Inhibitor Cocktail (PIC) (Sigma Aldrich) by
sonication followed by centrifugation at 12,000 rpm at 4 °C for 10 min. The
supernatant was collected and stored at −80 °C until further use. The concentra-
tion of the protein was estimated by Bicinchoninic Acid assay (BCA) method
(Pierce BCA protein Assay kit, Cat no: 23225) with varying concentrations of
Bovine Serum Albumin (BSA) as standards.
Protein lysates (150 μg) were mixed with approximately 1X sample loading
buffer (0.25 M Tris-HCl pH 6.8, 15% SDS, 50% glycerol, 25% β-mercaptoethanol,
0.01% bromophenol blue). The samples were denatured at 95 °C for 10 min and
run on 10% Sodium Dodecyl Sulfate - Polyacrylamide gel electrophoresis (SDS-
PAGE) at a constant voltage of 100 V for 90 min. The proteins were then
transferred onto a nitrocellulose membrane (wet transfer) at 100 V for 60 min. 5%
non-fat milk in PBS with 0.01% Tween 20 (PBST) was used as blocking reagent to
prevent non-specific binding. After blocking, the membrane was probed with anti-
CTPS (Sigma, Cat no: WH0001503 M1) or anti-CS (Sigma, SAB 2701077) primary
monoclonal antibody (1:1000 in PBST) and incubated overnight at 4 °C. The
membranes were washed thrice with PBST for 10 min at room temperature,
subsequently probed with respective HRP conjugated secondary goat Anti-Mouse
IgG HRP (Santa Cruz, Cat no: sc-2005) (1:3000 in PBST) and incubated for 2 h at
room temperature. After intermittent washes with PBST (3 × 10 min) to remove
the unbound secondary antibodies, the membrane was detected using a TMB
substrate. Protein lysates probed with anti-β actin primary monoclonal antibody
was used as an endogenous control for the Western blotting experiments. Results
were compiled as a mean of three independent experiments. The data are presented
as the Mean ± SD of at least three independent experiments.
Drosophila screen and imaging. GMR-G4-UAS-E2f1-RNAi/CyO virgin females
were crossed to UAS-RNAi lines targeting the proteins of interest. Each of the
UAS-RNAi lines were purchased from the Bloomington Drosophila Resource
Center (BDRC). 3 days after the cross was set, the adults were moved to a new vial
and then discarded 3 days later. Non-CyO progeny from each cross was inde-
pendently scored by blinded screeners and at the end of the screen, the scores were
merged. All modifiers were then re-crossed to GMR-G4-UAS-E2f1-RNAi/CyO for
confirmation, GMR-G4-UAS-GFP-RNAi/CyO to test whether the phenotype was
E2f1-RNAi dependent and PTC-G4-UAS-E2f1-RNAi/CyO to determine if each
line could modify non-eye E2f1-RNAi phenotypes.
For Scanning Electron Microscopy (SEM), the Drosophila were dehydrated in
increasing levels of ethanol before being critical point dried and imaged using the
CEMAS SEM facility at the Ohio State University. Multiple flies were imaged for
each modifier and representative images selected for inclusion in the paper.
Cell death assay. 5×104 cells were seeded in each well of a 24-well plate for RPE1-
WT and RB-KO clones. The cells were incubated overnight at 37 °C, 5% CO2
incubator and allowed to attach. 2-Deoxy Glucose (62.5 nM, Sigma #D8375) and
O-phospho-DL-serine (250 nM, Sigma #79710) were added to the treatment wells
with the corresponding vehicle control. The cells were placed in the 37 °C, 5% CO2
incubator for 72 h. Cells were then fixed in the crystal violet fixing solution and
stained with crystal violet for visualization.
Statistics and reproducibility. Statistical analysis of experimental data was con-
ducted using t-tests or ANOVA tests replicates. We define biological replicates as
cells harvested from independent experiments, and technical replicates as the
number of samples collected in multiple from each biological replicate. All cellular
experiments were conducted in biological and technical triplicates. Replicate
number and strategy for RNA-seq, proteomics and metabolomics are extensive
outlined in those sections. In brief, we used 2 independent shRNAs targeting pRB
or controls. Biological replicates were defined as cells expressing each shRNA and
technical replicates were generated by conducting the experiment in triplicate.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA-seq data from this work can be found at GEO accession number: GSE140383.
The proteomic data from this work can be found at the MassIVE data repository under
the accession number: MSV000084736. Source data underlying figures in the main text
and supplementary information are presented in Supplementary Data 4–5.
Code availability
All software and code used to process and analyze the data are described in the
“Methods”. These have been previously described in the literature and are common,
frequently utilized tools used to measure changes in omics studies.
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